Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Inclusion Criteria:

* primary refractory or relapsed AML
* confirmed diagnosis of AML (de novo or secondary) as defined by WHO classification (Vardiman 2002)
* aged at least 18 years

Exclusion Criteria:

* initial diagnosis of acute promyelocytic leukemia as defined by French-American-British criteria (Bennett 1976)
* patient in blast crisis stage of chronic myeloid leukemia
* received high-dose cytarabine (total cumulative dose of \>6g/m sq)in last 6 months
* interval of \<6 months between first onset of last complete remission and current relapse
* those with primary refractory leukemia who have received more than three previous induction cycles
* relapsed patients who have received more than three previous treatment regimens